Victoza Injection
Product Images NDC 50090-4503

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Victoza (NDC 50090-4503). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Structural Formula Of Liraglutide (49f302f5 F315 48b8 83a4 6ca56f01fded 01)

FDA Label Image

Figure 2 Mean Insulin Secretion Rate (isr) Versus Glucose Concentration (49f302f5 F315 48b8 83a4 6ca56f01fded 02)

Figure 2 Mean Insulin Secretion Rate (isr) Versus Glucose Concentration (49f302f5 F315 48b8 83a4 6ca56f01fded 02)
This is a graph showing the plasma glucose (measured in mg/dL) levels for two groups: one receiving a drug called Victoza and the other group receiving a placebo. The values on the x-axis range from 80 to 220, while the units on the y-axis are not specified. The text "15K {pmol/kg/min)" may be unrelated to this graph.*
FDA Label Image

Figure 4 Mean Hba1c For Patients Who Completed The 26-week Trial And For The Last Observation Carried Forward (locf, Intent-to-treat) Data At Week 26 (49f302f5 F315 48b8 83a4 6ca56f01fded 04)

FDA Label Image

Victoza Pen And Needle (Image 01)

Victoza Pen And Needle (Image 01)
This text appears to be a diagram or instruction manual for using a Victoza Pen, with illustrations of the rubber cartridge tip, stopper, dose display, needle, and needle protective covering. It also includes a phone number and website for help with using the pen.*
FDA Label Image

Fig. A (Pull off pen cap)

FDA Label Image

Fig. B (Remove protective tab.)

FDA Label Image

Fig. C And D (- Image 04)

FDA Label Image

Fig. E (Image 05)

FDA Label Image

Fig. F (Image 06)

FDA Label Image

Fig. G (Image 07)

FDA Label Image

Fig. H (Pull off pen cap.)

FDA Label Image

Fig. I (Image 09)

FDA Label Image

Fig. J-k (Image 10)

FDA Label Image

Fig. L (Image 11)

FDA Label Image

Fig. M (Image 12)

FDA Label Image

Fig. N (Image 13)

FDA Label Image

Fig. O (Image 14)

FDA Label Image

Fig. P (Image 15)

FDA Label Image

Fig. Q (Image 16)

FDA Label Image

Figure 5 (Image 20)

Figure 5 (Image 20)
The text describes a graph or table showing the results of a medical study comparing the drug Victoza to a placebo. The study tracked patients over time, with the x-axis showing months from randomization and the y-axis showing the number of patients at risk. The FAS (full analysis set) is mentioned. The graph or table shows that Victoza had a beneficial effect compared to the placebo, with a HR (hazard ratio) of 0.87 and a confidence interval of 95%.*
FDA Label Image

Figure 3 (Image 21)

Figure 3 (Image 21)
This appears to be a graph comparing the effectiveness of two diabetes medications, Glimepiride and Victoza, at different doses over time. The graph shows the change in glucose levels over the course of several weeks, with Victoza 1.8mg dosage being the most effective in lowering glucose levels compared to Glimepiride. There are also some statistical values provided in the text.*
FDA Label Image

Label Image (Lbl500904503)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.